Skip to content
Agentic OS
Menu

Intelligence / B2B SaaS / Acquisitions / Vivos Therapeutics, Inc.

M&Acompleted an acquisition (SEC 8-K)19 Oct 2026

Vivos Therapeutics, Inc.

19 Oct 2026: Completed an acquisition (SEC 8-K) · Medical devices. Recorded in the SEC EDGAR full-text search.

View the source record

Filed
19 Oct 2026
Ticker
VVOS
Role
Completed an acquisition
Sector
Medical devices
Sic
3841
Items
1.01, 2.01, 3.02, 3.03, 5.03, 7.01, 8.01, 9.01
Summary
On the Closing Date, the Company completed the acquisition of (i) 3,057,879 shares of common stock of SOD (the " SOD Shares "), representing at least eleven percent (11%) of SOD's fully diluted capital stock immediately after the Closing (as adjusted, in accordance with Section 1.1 of the Agreement, from the 2,907,338
Location
Littleton, CO
State
Colorado
Country
United States
SEC CIK
1716166
Reference
0001493152-26-047601
What this signal means

Integration means consolidating tools and vendors: the buyer re-platforms the target, and an acquired company's stack is reviewed by its new owner.

  1. Completed an acquisition leads with 189 of 292, then Sold assets or a business (82).
  2. 103 added in the 30 days to 19 Nov 2026.
Reach them with AOS

Find the decision makers at Vivos Therapeutics, Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this m&a signal, for your approval.

Start free

Across AOS Research

Other records for Vivos Therapeutics, Inc. in our registers.

More in Completed an acquisition

Acquisitions

See all

Source: SEC EDGAR full-text search, data to 19 Nov 2026. Every Form 8-K reporting Item 2.01 (completion of an acquisition or disposition of assets) filed with the SEC in the last 90 days. The role (buyer, company acquired, seller) is read from the filing's own wording, which is quoted on each row. AOS shows what the public record says; it does not verify or endorse the company.